A well-known adage reminds us that corporate insiders and 10% owners really only buy shares of a company because they believe the stock price will rise and they want to profit from it. Thus, insider buying can be an encouraging signal for potential investors.
Among the past week’s most notable insider buying, a biopharmaceutical company that recently received approval for its primary treatment had a director scooping up shares. A former CEO made a big purchase of a natural gas pipeline company as well. And a return buyer continued to boost a stake in an industrial products maker.
Let’s take a quick look at these notable transactions in the past couple of weeks.
This post originally appeared at 24/7 Wall St.